Literature DB >> 9207345

Distribution of hepatitis C virus (HCV) RNA in whole blood and blood cell fractions: plasma HCV RNA analysis underestimates circulating virus load.

W N Schmidt1, P Wu, J Q Han, M J Perino, D R LaBrecque, J T Stapleton.   

Abstract

Previous experiments using a cationic surfactant to detect hepatitis C virus (HCV) RNA in whole blood (WB) suggested that WB was a more plentiful source of viral RNA than was plasma. The relative HCV RNA titers in WB, plasma, peripheral blood mononuclear cells (PBMC), neutrophils, and red blood cells (RBC)/platelets from 10 patients with chronic HCV infection were compared. WB contained significantly more HCV RNA than plasma, which contained more HCV RNA than PBMC, neutrophils, or RBC/platelets (P < .001). To determine if this increased sensitivity was clinically relevant, results of WB and plasma HCV RNA assays were compared with commercial quantitative and qualitative plasma HCV RNA assay results obtained for patients receiving interferon therapy. WB was significantly more sensitive than commercial plasma reverse transcription-polymerase chain reaction for detecting HCV RNA (P < .005). These data indicate that a significant proportion of HCV RNA in peripheral blood is not identified by standard plasma RNA detection methods.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207345     DOI: 10.1086/514024

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  HCV-RNA positivity in peripheral blood mononuclear cells of patients with chronic HCV infection: does it really mean viral replication?

Authors:  V Meier; S Mihm; P Braun Wietzke; G Ramadori
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Whole-blood hepatitis C virus RNA extraction methods.

Authors:  W Schmidt; J T Stapleton
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

3.  Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.

Authors:  S Wünschmann; J D Medh; D Klinzmann; W N Schmidt; J T Stapleton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries.

Authors:  Victor J Drew; Lassina Barro; Jerard Seghatchian; Thierry Burnouf
Journal:  Blood Transfus       Date:  2017-04-13       Impact factor: 3.443

5.  Use of whole blood specimens for routine clinical quantitation of hepatitis C virus RNA does not increase assay sensitivity.

Authors:  L Cook; A M Ross; G B Knight; V Agnello
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

6.  Viral interactions with B-cells contribute to increased regulatory T-cells during chronic HCV infection.

Authors:  Chris L Ayers; Mihail Firan; Vinodh Pillai; William M Lee; Nitin J Karandikar
Journal:  Viral Immunol       Date:  2011-04       Impact factor: 2.257

7.  Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA.

Authors:  J T Stapleton; D Klinzman; W N Schmidt; M A Pfaller; P Wu; D R LaBrecque; J q Han; M J Phillips; R Woolson; B Alden
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

8.  Hepatitis C virus RNA quantitation in venous and capillary small-volume whole-blood samples.

Authors:  Tony Bruns; Katrin Steinmetzer; Eugen Ermantraut; Andreas Stallmach
Journal:  J Clin Microbiol       Date:  2009-08-19       Impact factor: 5.948

9.  Whole blood as an alternative to plasma for detection of hepatitis C virus RNA.

Authors:  Hubert Darius J Daniel; Joel David; Paul R Grant; Jeremy A Garson; George M Chandy; Priya Abraham
Journal:  J Clin Microbiol       Date:  2008-08-13       Impact factor: 5.948

10.  Interaction of immune complexes isolated from hepatitis C virus-infected individuals with human cell lines.

Authors:  Rafael Marino; Leopoldo Deibis; Juan B De Sanctis; Nicolas E Bianco; Felix Toro
Journal:  Med Microbiol Immunol       Date:  2005-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.